Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

CRANFORD, N.J., April 26, 2024 /PRNewswire/ — Citius Pharmaceuticals Inc. (Nasdaq: CTXR) (“Citius” or the “Company”), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 21,428,574 shares of its common stock and accompanying warrants to purchase up […]

April 26, 2024